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Summary
This follow-up extension of a randomised phase II study assessed differ-
ences in long-term outcomes between bortezomib-thalidomide-dexametha-
sone (VTD) and VTD-cyclophosphamide (VTDC) induction therapy in
multiple myeloma. Newly diagnosed patients (n = 98) were randomised 1:1
to intravenous bortezomib (13 mg/m2; days 1, 4, 8, 11), thalidomide
(100 mg; days 1–21), and dexamethasone (40 mg; days 1–4, 9–12), with/
without cyclophosphamide (400 mg/m2; days 1, 8), for four 21-day cycles
before stem-cell mobilisation/transplantation. After a median follow-up of
648 months, median time-to-next therapy was 518 and 479 months with
VTD and VTDC, respectively. Type of subsequent therapy was similar in
both arms. After adjusting for asymmetric censoring, median time to pro-
gression was not significantly different between VTD and VTDC [357 vs.
345 months; Hazard ratio (HR) 126, 95% confidence interval: 076–209;
P = 0370]. Five-year survival was 691% and 653% with VTD and VTDC,
respectively. When analysed by minimal residual disease (MRD) status,
overall survival was longer in MRD-negative versus MRD-positive patients
with bone marrow-confirmed complete response (HR 366, P = 00318).
VTD induction followed by transplantation provides long-term disease
control and, consistent with the primary analysis, there is no additional
benefit from adding cyclophosphamide. This study was registered at Clini-
calTrials.gov (NCT00531453).
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Bortezomib-based triplet combinations are among the estab-
lished standards of care as induction therapy for previously
untreated patients with multiple myeloma (MM) who are eli-
gible for high-dose therapy with autologous stem cell trans-
plantation (HDT-ASCT) (Anderson et al, 2013; Ludwig et al,
2014). Such combinations include bortezomib plus thalido-
mide and dexamethasone (VTD) – a regimen which has
recently been approved in the European Union, Canada and
Australia – and bortezomib plus cyclophosphamide and
dexamethasone (VCD), both of which are effective in previ-
ously untreated MM (Cavo et al, 2010; Reeder et al, 2010;
Moreau et al, 2011; Kumar et al, 2012; Rosi~nol et al, 2012a).
While the benefits of triplet combinations are proven, it has
not been established whether the addition of a fourth agent
might further improve the activity of these combinations
(Kumar et al, 2012), despite some evidence indicating the
potential of quadruplet regimens (Jakubowiak et al, 2011;
Palumbo et al, 2014).
We conducted an open-label, randomised non-comparative
phase II study to evaluate the efficacy and safety of VTD and
VTD plus cyclophosphamide (VTDC) as induction therapy
prior to HDT-ASCT in 98 patients with previously untreated
MM (Ludwig et al, 2013). Results from the primary analysis
conducted after a median follow up of 333 months showed
that both VTD and VTDC are active induction regimens,
resulting in bone marrow-confirmed complete response (CR)
rates of 29% and 31% post-induction, and 57% and 61%
post-HDT-ASCT, respectively. We also showed that 35% of
VTD and 27% of VTDC patients achieved minimal residual
disease (MRD)-negative status, which is a prognostic indica-
tor of improved outcomes, particularly among patients achiev-
ing a ‘conventional’ CR (Korthals et al, 2012; Rawstron et al,
2013; Martinez-Lopez et al, 2014; Puig et al, 2014). At the
time of the primary analysis, no significant differences in sur-
vival outcomes were seen, suggesting no benefit from the addi-
tion of cyclophosphamide to VTD. However, as outcomes
data were not mature at this analysis, with only 21% of
patients having progressed and 15% having died, we now
report the findings from the protocol-specified, long-term
extension follow-up phase of the study, which evaluated final
time-to-event data after a median follow-up of more than
5 years. Experience from other trials (Mateos et al, 2014; Pal-
umbo et al, 2014) indicates that subtle differences in outcome
may only become detectable after long follow-up when the
treatment impact on good risk patients becomes evident. In
addition, data on subsequent MM treatment are reported,
together with analyses of outcomes according to MRD status
and depth of response.
Methods
Patients and study design
The design of this randomised, non-comparative multicentre
phase II study (clinicaltrials.gov identifier: NCT00531453)
has been reported previously (Ludwig et al, 2013). Briefly,
transplant-eligible patients aged 18–70 years with previously
untreated, measurable MM and without grade ≥2 peripheral
neuropathy or neuropathic pain [National Cancer Institute
Common Terminology Criteria for Adverse Events version
3.0 (http://ctep.cancer.gov/protocolDevelopment/electronic_
applications/docs/ctcaev3.pdf)] were randomised [1:1, strati-
fied by International Staging System (ISS) disease stage (Gre-
ipp et al, 2005)] to receive initial treatment with four 21-day
cycles of VTD or VTDC. Treatment comprised bortezomib
13 mg/m2 intravenously on days 1, 4, 8 and 11, thalidomide
100 mg orally on days 1–21 and dexamethasone 40 mg orally
on days 1–4 and 9–12, with or without cyclophosphamide
400 mg/m2 intravenously on days 1 and 8. Patients who
remained eligible for transplant then underwent stem cell
mobilisation and single or double transplantation, while
patients who had become transplant-ineligible or had
achieved a CR post-induction could receive four additional
cycles of VTD or VTDC.
Institutional review boards or independent ethics commit-
tees at all participating sites approved the study, which was
conducted in accordance with the International Conference
on Harmonisation for Good Clinical Practice and the Decla-
ration of Helsinki. All patients provided written informed
consent.
Assessments
Responses were determined by independent review per Inter-
national Myeloma Working Group (IMWG) uniform
response criteria (Durie et al, 2006), with the additional
response categories of CRflc [defined as CR with a norma-
lised serum free light chain (FLC) ratio; used as a surrogate
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for stringent CR due to the lack of routine j/k bone marrow
staining] and near-CR (defined as absence of M-protein on
electrophoresis and immunofixation-positive). Post-trans-
plant, patients were followed every 12 weeks until disease
progression, and then every 12 weeks for survival and subse-
quent therapies. The primary endpoint of the study was the
combined rate of CRflc plus CR and near-CR post-induction.
Secondary endpoints included time to progression (TTP),
progression-free survival (PFS) and overall survival (OS).
Additionally, an exploratory analysis of time-to-next ther-
apy (TTNT; defined as the time from randomisation to the
start of subsequent MM therapy or death prior to subsequent
therapy) was conducted. Outcomes (PFS and OS) among
patients achieving bone marrow-confirmed CR were also
investigated according to MRD status. Among patients
achieving MRD-negative status, outcomes were also investi-
gated according to response (CRflc versus other responses).
For MRD assessment, bone marrow aspirates were col-
lected at suspected CR and, where possible, at screening.
MRD status was assessed at a central laboratory in Salamanca
by immunophenotyping using multiple staining combina-
tions [CD38 (Alexa Fluor)/-/CD56-PE/CD45-AmCyan/
CD19-PerCP-Cy5.5/CD138-APC, and CD38/ck-FITC/cj-PE/
CD45-AmCyan/CD19-PerCP-Cy5.5/CD138-APC], with the
aim of identifying, quantifying and characterising plasma
cells. Data were acquired in a FACSCantoTM II flow cytometer
(BD Biosciences, San Jose, CA, USA), using FACS DivaTM
(BD Biosciences) software to acquire information, and Infini-
cytTM software (Cytognos, Salamanca, Spain) for data analysis
by a central provider (Hospital Universitario de Salamanca,
Spain). Samples were characterised as MRD-positive if clonal
plasma cells were detected [based on increased expression of
CD19 and/or CD45 and/or increased expression of CD56,
together with immunoglobulin light chain restriction (cytopl-
asmaticK or cytoplasmaticL)], or MRD-negative if only nor-
mal and polyclonal plasma cells were detected.
Statistical analyses
The Kaplan–Meier method was used to estimate the distribu-
tion of time-to-event endpoints. Hazard ratios (HRs) and
95% confidence intervals (CIs) were estimated based on a
Cox’s model stratified by ISS disease stage, and P-values for
differences between treatment arms and patient groups were
calculated using the log-rank test stratified by ISS disease
stage.
For the primary analyses of TTP and PFS, patients who
were lost to follow-up, withdrew consent or received subse-
quent MM therapy due to early indicators of progression,
without fulfilling the standard criteria for disease progression,
were censored. To mitigate the effect of asymmetric censor-
ing between arms, sensitivity analyses of TTP and PFS were
conducted in which patients who received subsequent ther-
apy without meeting the standard IMWG criteria (Durie
et al, 2006) for disease progression were regarded as having
had a progression event if reported by the investigator as
having ‘relapsed from CR’ or having experienced ‘clinical
relapse’.
All analyses were undertaken by the sponsor. All authors
had access to the primary clinical trial data.
Results
Patients and follow-up
As previously reported (Ludwig et al, 2013), a total of 98
patients were enrolled and randomised to receive VTD or
VTDC (n = 49 in each arm) (see Fig S1). Median age was
57 years (range 35–65) and 58 years (range 33–68) in the
VTD and VTDC arms, respectively, and 24%/45%/31% and
18%/47%/35% of patients, respectively, had ISS stage I/II/III
disease. Other baseline characteristics were similarly well bal-
anced between the arms (Ludwig et al, 2013).
All patients had completed VTD or VTDC treatment at
the time of the initial report of the study (Ludwig et al,
2013). In both arms, patients received a median of four
treatment cycles. Forty-eight (98%) patients in the VTD arm
and 40 (82%) patients in the VTDC arm underwent
HDT-ASCT.
The data cut-off for this final pre-specified, long-term
extension analysis was 23 September, 2013; 5 years after the
last patient was randomised. The overall median follow-up,
calculated using reverse censoring, was 648 months in all
98 patients: 653 months in the VTD arm and 647 months
in the VTDC arm. This represents an additional follow-up
of approximately 32 months in each arm, based on the
medians, when compared with the initial report of the
study (Ludwig et al, 2013). At the time of data cut-off, 34
patients had died (15 VTD, 19 VTDC), 1 (2%) VTD
patient was lost to follow-up and 1 (2%) VTD patient had
chosen to withdraw from study data collection (see Fig S1).
Deaths were primarily due to disease progression: 10 (20%)
patients in the VTD arm and 15 (31%) patients in the
VTDC arm.
Long-term outcomes
At data cut-off for this protocol-specified final analysis,
per investigator assessment in the intent-to-treat popula-
tion, 20/49 (41%) patients in the VTD arm and 32/49
(65%) in the VTDC arm had disease progression events in
the TTP analysis, and 24/49 (49%) and 34/49 (69%)
patients had PFS events (disease progression or death).
Median TTP in this primary analysis was not reached with
VTD versus 393 months with VTDC [HR 155 (95% CI:
088–272), P = 0125], and 5-year progression-free rates
were 541% and 306%, respectively (Fig 1A). Median PFS
was 563 vs. 363 months with VTD versus VTDC [HR
137 (95% CI: 081–231), P = 0244], and the respective
5-year PFS rates were 478% and 291% (Fig 1C).
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Fig 1. Time to progression (TTP) and progres-
sion-free survival (PFS) with VTD and VTDC.
(A) TTP per the primary analysis, with asym-
metric censoring between arms. (B) TTP per
the sensitivity analysis. (C) PFS per the pri-
mary analysis. (D) PFS per the sensitivity
analysis. CI: confidence interval; HR: hazard
ratio; NE: not estimatable; VTD, bortezomib-
thalidomide-dexamethasone; VTDC,
bortezomib-thalidomide-dexamethasone plus
cyclophosphamide.
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Asymmetric censoring was seen between 24 and
54 months in the primary analysis of TTP/PFS. In the VTD
arm, 10 patients were censored in the analysis of TTP
(Fig 1A) and 8 in the analysis of PFS (Fig 1C) during this
follow-up period, compared with no patients in the VTDC
arm. Of the 10 VTD patients censored in the TTP analysis, 2
were censored due to study data cut-off and 1 was lost to
follow-up; the other 7 patients were censored due to starting
subsequent therapy following a recorded ‘relapse from CR’
or ‘clinical relapse’ in the absence of investigator-docu-
mented disease progression per IMWG criteria (Durie et al,
2006). Therefore, to mitigate the impact of this asymmetric
censoring, a sensitivity analysis of TTP and PFS was con-
ducted in which these patients were considered as having an
event at the time of recorded ‘relapse from CR’ or ‘clinical
relapse’. Results from the sensitivity analysis are summarised
in Table I. Using this approach, median TTP was 357 vs.
345 months with VTD and VTDC, respectively [HR 126
(95% CI: 076–209), P = 0370; Fig 1B], and median PFS
was 341 vs. 342 months [HR 120 (95% CI: 074–197),
P = 0461; Fig 1D].
To further evaluate the impact of asymmetric censoring
on apparent differences in long-term outcomes between
arms, an exploratory analysis of TTNT was conducted
(Table I; Fig 2A). In this analysis, median TTNT was 518 vs.
479 months with VTD versus VTDC [HR 121 (95% CI:
071–205), P = 0484], with 26 (53%) and 30 (61%)
patients, respectively, having received subsequent therapy or
died due to disease progression prior to receiving subsequent
therapy at data cut-off. Eight (16%) and 6 (12%) patients
received at least three more lines of therapy, and 14 (29%)
and 12 (25%) received at least two more lines of therapy in
the VDT and VDTC treatment groups, respectively. The
agents most commonly received as part of subsequent ther-
apy included dexamethasone, lenalidomide, bortezomib, tha-
lidomide and cyclophosphamide (Table II). The type of
Table I. Time to progression (TTP) and progression-free survival (PFS) per investigator assessment (sensitivity analysis), time-to-next therapy
(TTNT) and overall survival (OS) in the VTD and VTDC arms, based on Kaplan–Meier product limit estimates.
Outcome
VTD
(n = 49)
VTDC
(n = 49) HR (95% CI) P*
TTP (sensitivity analysis)
Events, n (%) 27 (55) 35 (71)
Median (95% CI), months 357
(239–NE)
345
(235 –506)
126
(076–209)
0370
3-year rate, % (95% CI) 488
(339–621)
479
(333–611)
NA NA
5-year rate, % (95% CI) 418
(275–555)
271
(155–400)
NA NA
PFS (sensitivity analysis)
Events, n (%) 29 (59) 36 (74)
Median (95% CI), months 341
(235–NE)
342
(235–482)
120
(074–197)
0461
3-year rate, % (95% CI) 468
(324–599)
469
(326–600)
NA NA
5-year rate, % (95% CI) 401
(262–535)
265
(152 –393)
NA NA
TTNT
Events, n (%) 26 (53) 30 (61)
Median (95% CI), months 518
(319–NE)
479
(287–NE)
121
(071–205)
0484
OS
Events, n (%) 15 (31) 19 (39)
Median (95% CI), months NE
(NE–NE)
NE
(643–NE)
115
(058–227)
0692
3-year rate, % (95% CI) 796
(654–885)
837
(700–915)
NA NA
5-year rate, % (95% CI) 691
(541–801)
653
(503–768)
NA NA
HR, hazard ratio; CI, confidence interval; NE: not estimable; NA: not applicable; VTD, bortezomib-thalidomide-dexamethasone; VTDC, bortezo-
mib-thalidomide-dexamethasone plus cyclophosphamide.
*Based on a stratified log-rank test.
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subsequent therapy was similar in both treatment groups; 15
(31%) and 16 (33%) patients were retreated with bortezo-
mib, and 9 (18%) and 8 (16%) patients were retreated with
thalidomide.
Median OS was not reached in either arm (Table I;
Fig 2B). Five-year survival rates were 691% with VTD and
653% with VTDC.
Outcomes by depth of response and minimal residual
disease status
To assess the relationship between depth of response and
long-term outcomes, PFS and OS were analysed in patients
achieving CRflc (CR with normal FLC ratio confirmed by
bone marrow plasma cells, but without bone marrow immu-
nohistochemistry; n = 32) at any point in the study versus
≥very good partial response (VGPR) but excluding the 32
patients with CRflc (n = 48) versus <VGPR (n = 18). This
analysis was pooled across the VTD and VTDC arms. As
expected, there was a trend for better PFS and OS in the true
CR (CRflc) versus ≥VGPR versus <VGPR groups. Across both
arms combined, median (95% CI) PFS was 563 months
(357–not estimable) in the CRflc group, 386 months (263–
not estimable) in the ≥VGPR group and 260 months (102–
347) in the <VGPR group. In the sensitivity analysis, median
(95% CI) PFS was 469 months (239–not estimable) in the
CRflc group, 306 months (232–not estimable) in the
≥VGPR group and 260 months (102–347) in the <VGPR
group. Median (95% CI) OS was not reached in the CRflc or
≥VGPR groups, but was 669 months (350–not estimable) in
the <VGPR group (Fig 3A).
A total of 42 patients with bone marrow-confirmed CR
were available for analysis of outcomes (PFS and OS) accord-
ing to MRD status: 34 were MRD-negative and 8 were
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Fig 2. Time-to-next therapy (TTNT) and over-
all survival (OS) with VTD and VTDC. (A)
TTNT. (B) OS. CI: confidence interval; HR:
hazard ratio; NE: not estimatable; VTD, bort-
ezomib-thalidomide-dexamethasone; VTDC,
bortezomib-thalidomide-dexamethasone plus
cyclophosphamide.
Table II. Agents commonly received (≥10% of patients overall) as
part of subsequent therapy following VTD or VTDC.
Agent
VTD
(n = 49)
VTDC
(n = 49)
n % n %
Any subsequent therapy 24 49 28 57
Dexamethasone 20 41 21 43
Lenalidomide 17 35 16 33
Bortezomib 15 31 16 33
Thalidomide 9 18 8 16
Cyclophosphamide 6 12 10 20
Melphalan 3 6 8 16
Doxorubicin 4 8 6 12
VTD, bortezomib-thalidomide-dexamethasone; VTDC, bortezomib-
thalidomide-dexamethasone plus cyclophosphamide.
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MRD-positive by multiparameter flow cytometry. In the pri-
mary analysis of PFS, median was not reached in MRD-nega-
tive patients versus 386 months in MRD-positive patients
[HR 229 (95% CI: 087–604), P = 0085]. Per the PFS sen-
sitivity analysis, respective medians were 469 versus
386 months [HR 151 (95% CI: 061–377), P = 0373]. OS
was longer in MRD-negative versus MRD-positive patients
[median not reached in either group; HR 366 (95% CI:
103–1301), P = 0032; Fig 3B].
Including those patients who achieved <CR, 42 patients
achieved MRD-negative status across the VTD and VTDC
groups. Twenty-four of these patients had a best response of
CRflc, 14 had a response of CR (bone marrow-confirmed)
and 4 had a response of <CR [1 near complete response
Months from randomisation
0
0
10
20
30
CRflc
P
at
ie
nt
s 
al
iv
e 
(%
)
40
50
60
70
80
90
100
6 12 24 36 48 60 7218 30 42 54 66
≥VGPR but not CRflc
<VGPR
Median OS
CRflc: NE
≥VGPR (but not CRflc): NE
<VGPR: 66·9 months
Patients at risk
CRflc
≥VGPR but not CRflc
<VGPR
32
48
18
32
48
17
31
46
16
30
45
15
29
45
15
29
43
14
28
39
13
27
36
13
26
33
12
25
31
12
25
28
10
9
9
5
0
0
0
(A)
Months from randomisation
0
0
10
20
30
P
at
ie
nt
s 
al
iv
e 
(%
)
40
50
60
70
80
90
100
8 16 28 40 52 64 7232 48 603624124 68564420
0 8 16 28 40 52 64 7232 48 603624124 68564420
MRD-negative
MRD-positive
Median OS
MRD-negative: NE
MRD-positive: NE (HR 3·66 [95% Cl: 1·03–13·01], P = 0·032)
(B)
Patients at risk
Negative
Positive
34
8
34
8
34
8
34
7
34
7
33
7
33
6
33
6
33
6
32
5
29
5
29
4
29
4
28
4
28
4
27
4
4
3
20
3
0
0
Months from randomisation
0
10
20
30
P
at
ie
nt
s 
al
iv
e 
(%
)
40
50
60
70
80
90
100
Median OS
CRflc: NE
Other: NE (HR 0·56 [95% Cl: 0·15–2·09], P = 0·381)
Patients at risk
CRflc
Other
24
18
24
18
24
18
24
17
24
17
23
17
23
17
23
17
23
17
23
16
21
15
21
15
21
15
20
15
20
15
15
8
20
12
4
1
0
0
(C) CRflc
Other
Fig 3. Overall survival (OS) according to mini-
mal residual disease (MRD) status and
response (pooled across VTD and VTDC
arms). Kaplan–Meier analyses of OS in: (A)
patients who achieved CRflc, ≥VGPR but
excluding the CRflc patients, or <VGPR; (B)
patients with bone marrow-confirmed CR who
were MRD-negative or MRD-positive; (C)
MRD-negative patients who achieved CRflc or
other responses. CI: confidence interval; CR:
complete response; CRflc: CR with normalized
serum free light chain ratio; HR: hazard ratio;
NE: not estimatable; VGPR: very good partial
response; VTD, bortezomib-thalidomide-dexa-
methasone; VTDC, bortezomib-thalidomide-
dexamethasone plus cyclophosphamide.
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(nCR), 1 VGPR, 2 PR]. PFS and OS were evaluated in the 24
MRD-negative CRflc patients versus the 18 MRD-negative
patients achieving ≤CR. In the primary analysis of PFS, med-
ian was not reached versus 599 months in MRD-negative
CRflc versus ≤CR patients, respectively [HR 101 (95% CI:
040–257), P = 0982]; in the sensitivity analysis, median
PFS was 469 versus 558 months [HR 097 (95% CI: 044–
214), P = 0941]. Median OS was not reached in either
group of MRD-negative patients [HR 056 (95% CI: 015–
209), P = 0381; Fig 3C].
Safety
There were no new adverse events reported in the study
database since the initial report of the study. In addition, no
second primary malignancies were reported during the long-
term extension phase.
Discussion
At a median follow-up of 645 months, equating to nearly
3 years of additional follow-up compared with the primary
analysis, data from this phase II extension study (Ludwig et al,
2013) demonstrate that VTD or VTDC induction followed by
HDT-ASCT provides long-term disease control for patients
with previously untreated MM. Across both treatment arms,
median time until patients required second-line therapy was
approximately 4 years and approximately two-thirds of patients
were alive at 5 years post-randomisation. Consistent with the
primary analysis (Ludwig et al, 2013), there were no statistically
significant differences in long-term outcomes between the two
treatment arms, and outcomes (TTP and PFS) were numerically
very similar once asymmetric censoring had been accounted
for. A total of 42 (43%) patients achieved MRD-negativity,
highlighting the high activity of the VTD and VTDC induction
protocols used here. In the prognostic analyses, patients who
achieved MRD-negativity had particularly promising out-
comes, with 5-year OS rates of approximately 80% and signifi-
cantly better median OS (HR 366, P = 0032) than patients
who remained MRD-positive. Achievement of CRflc versus
‘standard’ CR or less, however, did not confer additional prog-
nostic significance in MRD-negative patients. The current
analysis thus suggests that MRD-negativity (versus MRD-posi-
tivity) may be a stronger prognostic marker for OS than bone
marrow-confirmed CRflc [versus other responses (CR/nCR/
VGPR/PR)].
Despite a lack of statistically significant differences, the
numerical differences in TTP and PFS between the two treat-
ment arms prompted us to check for potential confounding
factors. It was observed that there was a marked difference
between the two arms in the number of patients who were cen-
sored between 24 and 54 months’ follow-up. This ‘asymmetric
censoring’ was caused predominantly by VTD patients receiv-
ing subsequent therapy due to ‘relapse from CR’ or ‘clinical
relapse’ before they had been recorded as having progressive
disease per IMWG criteria (Durie et al, 2006). To account for
this censoring imbalance, and potential limitation of the study,
TTP and PFS analyses were re-run so that these patients were
considered as having an event at the time of recorded ‘relapse
from CR’ or ‘clinical relapse’. Using this approach, the sensi-
tivity analyses revealed very similar median TTP and PFS dura-
tions in the VTD and VTDC treatment arms [median TTP,
357 vs. 345 months (HR 126, P = 0370); median PFS 341
vs. 342 months (HR 120, P = 0461), respectively]. The find-
ings of the exploratory analysis of TTNT [median 518 vs.
479 months (HR 121, P = 0484)] were also consistent both
with those seen in the sensitivity analyses of TTP and PFS, and
with the lack of difference in OS between arms, supporting the
finding of no meaningful differences in long-term outcomes
between the two treatment arms. Additionally, the number
and type of subsequent lines of therapy were similar in both
treatment groups.
Our findings of high activity of VTD induction (Ludwig
et al, 2013) that persists over the long term are consistent with
results reported for the VTD regimen in the Gruppo Italiano
Malattie Ematologiche dell’Adulto (GIMEMA) MMY-3006
(Cavo et al, 2010, 2012, 2013) and Programa para el Estudio
de la Terapeutica en Hemopatıas Malignas/Grupo Espa~nol de
MM (PETHEMA/GEM) phase III (Rosi~nol et al, 2012a,b) tri-
als in newly diagnosed MM, and confirm VTD as one of the
most clinically active regimens in this setting. This is supported
by a recent meta-analysis showing significant superiority of
VTD over VCD, both in terms of activity and of tolerance (Lei-
ba et al, 2014), and by a retrospective comparison of the VTD
and VCD arms of large European trials (Cavo et al, 2014).
High activity has also been reported with other proteasome
inhibitor-based triplet induction regimens, such as bortezo-
mib-doxorubicin-dexamethasone (PAD) (Sonneveld et al,
2012, 2013), bortezomib-lenalidomide-dexamethasone (VRD)
(Kumar et al, 2012), and carfilzomib-lenalidomide-dexameth-
asone (Jakubowiak et al, 2012). In the present extension study,
addition of a fourth agent, cyclophosphamide, to the VTD
triplet did not result in any improvement in efficacy, which is
in accordance with the primary analysis data (Ludwig et al,
2013). This observation is also supported by evidence from a
previous study, in which a quadruplet regimen incorporating
lenalidomide instead of thalidomide [VRD-cyclophosphamide
(VRDC)] was found to yield similar outcomes to triplet induc-
tion therapy (VCD or VRD) in previously untreated, trans-
plant-eligible patients with MM (Kumar et al, 2012). In
contrast, data from a randomised study conducted in newly
diagnosed, transplant-ineligible patients suggested that the
quadruplet regimen of VMP-thalidomide (VMPT) may be
associated with better outcomes (CR rate, PFS, TTNT and OS)
than VMP alone (Palumbo et al, 2014). However, not only
were these findings in transplant-ineligible patients, it should
also be noted that VMPT induction was followed by mainte-
nance with bortezomib-thalidomide, whereas no maintenance
was used in the VMP arm, and the induction responses were
not consolidated with transplantation. Furthermore, when the
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data were first published after a median follow-up of
232 months, no difference in OS was noted (Palumbo et al,
2010). Survival curves diverged significantly only after pro-
longed follow-up (median 54 months) (Palumbo et al, 2014),
indicating the importance of long-term observation for con-
clusive evaluation of the impact of a treatment strategy. VMPT
was also less well tolerated than VMP (Palumbo et al, 2014).
Multiparameter flow cytometry is a highly sensitive tech-
nique for evaluation of MRD in MM that seems to offer sim-
ilar sensitivity to the polymerase chain reaction (Hart et al,
2012; Martinez-Lopez et al, 2014; Puig et al, 2014). The
flow-MRD assay used here benefited from a 6-colour
approach that confirmed the clonal nature (through light-
chain restriction) of phenotypically aberrant plasma cells.
Using this technique, we showed that MRD-negative patients
had significantly longer OS than those who were MRD-posi-
tive, a finding supported by data from other recent studies in
the literature (Korthals et al, 2012; Rawstron et al, 2013;
Martinez-Lopez et al, 2014; Puig et al, 2014). Current efforts
are now underway to develop an automated flow-MRD
method based on 10-colour approaches, with similar sensitiv-
ity to next-generation sequencing techniques. The similar
PFS or OS among MRD-negative patients achieving CRflc
versus lower responses confirms the superiority of MRD as a
marker for long-term outcomes in newly diagnosed MM
over achievement of a true CR, which requires negative im-
munofixation. As the detection limit of this technique is
around 150 mg/l (Tate et al, 2009), the presence of a sub-
stantial number of myeloma cells may be missed. Alterna-
tively, M-protein may be detectable due to the unusually
long half-life of certain M-proteins, with recycling of IgG by
IgG FcRn receptors (Mead et al, 2004; Paiva et al, 2011)
being one potential cause of this phenomenon.
In summary, our long-term follow-up data support the
notion that three-drug bortezomib-based induction regimens
are the most appropriate therapies for previously untreated,
transplant-eligible MM. They also confirm VTD as a highly
active regimen, providing high response rates and notable
long-term outcome data following a limited period of induc-
tion therapy of only four cycles. Lastly, these analyses support
the prognostic benefit of achieving MRD-negative status and
the importance of this as a goal of first-line therapy in MM.
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